Although the mechanism of action of aspirin in reducing cancer progression is not clear, the rational conclusion to be drawn from available epidemiologic and pharmacokinetic data is that much of this beneficial effect is due to inhibition of platelet COX-1. The gene discussed is PTGS1; the disease is cancer.